Drug Trial Radar · NCT02802228
Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients
Last checked: Nov 19, 2026Latest source record: Jan 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 6, 2017
Primary completion
Jul 17, 2018
Study completion Jul 17, 2018
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This placebo-controlled study will assess the safety and efficacy of a 90-day course of treatment with ifetroban for portal hypertension in cirrhotic patients
Conditions
- Portal Hypertension
- Liver Cirrhosis
Interventions
IfetrobanDrug
thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
PlaceboDrug
matched placebo delivered as infusion and oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (Incidence and Severity of Adverse Events)Time frame: Through 97 days (90 days treatment and 7 days follow-up)
- Safety (Severity of Adverse Events)Time frame: Through 90 days treatment and 7 days follow-up
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Tampa General Medical Group
Tampa, Florida
Indiana University
Indianapolis, Indiana
The Ohio State University Wexner Medical Center
Columbus, Ohio
Medical University of South Carolina
Charleston, South Carolina
Baylor University Medical Center
Dallas, Texas
Virginia Commonwealth University Medical Center
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.